McKesson Corporation announced changes to its reportable business structure. The company has revised its reportable segments commencing in the second quarter of fiscal 2021.
Under the realignment, McKesson will have four reportable segments. The new reportable segments are:
Medical-Surgical Solutions
- Led by Stanton McComb, president
- Unaffected by the realignment
U.S. Pharmaceutical and Specialty Solutions (USPSS) becomes U.S. Pharmaceutical (USP)
- Led by Kirk Kaminsky, president
- Focus will continue to be wholesale drug distribution and value-added technology solutions for retail pharmacies, health systems, payers, and community providers
- Will also continue with the company’s comprehensive solutions offered through The US Oncology Network, US Oncology Research, McKesson Data Evidence and Insights, and Biologics by McKesson specialty pharmacy
Prescription Technology Solutions (RxTS)
- New reportable segment bringing together RelayHealth, CoverMyMeds, and RxCrossroads by McKesson to serve the company’s biopharma and life sciences partners
- Led by Nathan Mott, president
- Connects pharmacies, providers, payers and biopharma for next-gen. patient access and adherence solutions
International
- Newly established reportable segment
- Combines McKesson Canada and McKesson Europe
- Led by Kevin Kettler, who will also retain responsibilities as CEO and chairman of the management board for McKesson Europe
- Domenic Pilla remains CEO of McKesson Canada
- Brings together non-U.S.-based drug distribution services, specialty pharmacy, retail and infusion care services
- Focus will be enabling and accelerating the delivery of affordable, quality healthcare solutions
- Will further leverage the company’s scale and reach to drive value across key differentiators like the company’s owned retail pharmacy assets